M. K. Proteins Ltd Q1 FY27 Results

MKPLQ1 FY27 ResultsAnnounced 13 Aug, 4:43 pm

Result:WeakMargin squeezeCost led

Metric	Value	Q4 FY26	Q1 FY26
Revenue	115.16 Cr	21.1%	0.2%
Total Income	115.16 Cr	21.1%	0.2%
Expenditure	113.31 Cr	21.5%	2.8%
PBT	1.85 Cr	7.6%	60.7%
Net Profit	1.38 Cr	21.4%	60.6%
OPM	2.18%	0.47pp	2.61pp
NPM	1.20%	0.42pp	1.86pp
EPS	0.04	33.3%	55.6%

View full financials

Revenue was flat YoY but adjusted PAT fell 60.7% and EBITDA margin compressed sharply (4.79%→2.18%) as manufacturing and employee costs outran flat revenue, a clear below-par print for an FMCG/edible-oil manufacturer.

Q1 FY-2027 RESULTS · MKPL

MK Proteins Q1 FY27: standalone PAT falls 61% YoY as costs outpace flat revenue

PAT -60.65% YoY · revenue +0.19% · margins compressing

13 Aug 2026 · 3 min read

Revenue

₹115.16 Cr

+0.19% YoY

PAT (standalone)

₹1.38 Cr

-60.65% YoY

Net margin

1.2%

-1.9pp YoY

EPS

₹0.04

M. K. Proteins posted standalone revenue of ₹115.16 Cr in Q1 FY27, almost flat YoY (+0.19% from ₹114.95 Cr) but PAT fell 60.65% YoY to ₹1.38 Cr from ₹3.51 Cr, with EPS down to ₹0.04 from ₹0.09. There is no analyst/street coverage or consensus estimate available for this micro-cap edible-oil manufacturer, and neither our records nor a web search turned up any prior management guidance — so the print cannot be benchmarked against street or company guidance; both are unknown/not on record. Sequentially, revenue fell 21.09% from a seasonally stronger Q4 FY26 (₹145.94 Cr) but PAT rose 21.45% QoQ from ₹1.14 Cr, aided by a much smaller inventory-drawdown expense this quarter (₹3.46 Cr vs ₹16.76 Cr in Q4).

The scoreboard

Q1 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore

	Q1 FY-2027	QoQ	YoY
Revenue	₹115.16 Cr	-21.1%	+0.2%
Expenses	₹113.31 Cr	-21.5%	+2.8%
PAT	₹1.38 Cr	+21.45%	-60.65%
Net margin	1.2%	+0.4pp	-1.9pp
EPS	₹0.04	+33.3%	-55.6%

The YoY margin squeeze is the story: NPM narrowed to 1.20% from 3.06% and EBITDA margin to roughly 2.18% from 4.79%. Total expenses grew 2.79% YoY versus flat revenue, driven by manufacturing/operating expenses nearly doubling (₹5.18 Cr vs ₹2.84 Cr, +82%), employee costs up 46% (₹0.78 Cr vs ₹0.54 Cr), and a larger inventory-related expense swing (₹3.46 Cr vs ₹1.46 Cr) — partly offset by 27% lower finance costs (₹0.52 Cr vs ₹0.70 Cr) and lower stock-in-trade purchases. No management press release accompanied this filing, so there is no company commentary to reconcile against the numbers. The only corporate development flagged alongside the results is the resignation of independent director Laxmi Mandal effective 12 August 2026, a governance item unconnected to the financial performance.

₹

The tape into the print — daily closes, last 3 months

The stock went into the print at ₹4.16, down 7.6% over the past month of trading.

₹ Cr

Quarterly standalone PAT, ₹ Crore

W1
Whether YoY margin compression (EBITDA margin 2.18% vs 4.79% a year ago) reverses in Q2 FY27, contingent on manufacturing/employee cost growth falling back below revenue growth
W2
Q1 FY27 PAT of ₹1.38 Cr is only ~20% of full FY26 PAT (₹6.83 Cr) despite Q1 being ~30% of FY26 revenue (₹383.13 Cr) — an early read on whether full-year FY27 margins stay compressed
W3
Board composition following independent director Laxmi Mandal's resignation (effective 12 Aug 2026) — whether a replacement is appointed

Standalone-only reporter (no consolidated statement in filing); no exceptional/extraordinary items in either current or year-ago quarter so no adjusted-growth figure is needed; unaudited, limited-review by Subhash Sajal & Associates; independent director Laxmi Mandal's resignation disclosed same day as results. A web search for street estimates returned data for 'Mukka Proteins Ltd' (a different, unrelated fish-meal company) — that data was discarded as not applicable to M. K. Proteins Ltd (MKPL).